Pharmaceutical companies face numerous hurdles during early development, from API manufacturing to drug product formulation to clinical supply logistics.  Navigating these hurdles with speed is critical in the race to reach Phase I. One solution to maintaining that speed while mitigating risk is to work with a partner who specializes in numerous facets of drug development within one network.

Join this webinar to hear Thermo Fisher Scientific experts discuss how a simplified supply chain may help increase efficiency and reduce risk as your move to your Phase I milestone. They will also cover the latest enhancements to Thermo Fisher’s Quick to Clinic™ offering for Oral Solids, which now includes API manufacturing and essential solid state chemistry services.

Featured Speakers

Kevin Kane, PhD

Global SME
Thermo Fisher Scientific

Kevin provides technical consulting for drug delivery, early formulation development programs, and scale-up.  He focuses on finding solutions that align with a client’s clinical study design for small molecules with biopharmaceutic and physicochemical challenges. Kevin brings more than 25 years of industrial experience in synthesis, formulation and solubilization technologies (oral and sterile), and adaptive clinical studies, having worked as an independent consultant and as a scientist at various CDMOs in addition to his 9 years at Patheon Thermo Fisher. Kevin has a PhD Inorganic Chemistry (Ohio University), MS Polymer Chemistry and BS Chemistry (Texas State University).

Iain McGroarty, PhD

Senior Business Development Executive, API Europe
Thermo Fisher Scientific

Dr. Iain McGroarty has over 18 years of experience in the pharmaceutical and life sciences sector. Iain joined Thermo Fisher Scientific in September 2019 with the responsibility of promoting small molecule services in Europe. He started his career in the pharmaceutical industry back in 2002 when he joined AstraZeneca (Charnwood) as a research scientist working on the development of new solid dosage pharmaceuticals. Iain entered the contract development and manufacturing space in 2005 and has held a number of technical, project management and commercial roles in the sterile fill and finish, oral solid dosage and API sectors. Over the years, Iain has gained extensive knowledge of pharmaceutical development from preclinical to commercial. Iain has a PhD and MSc in Pharmaceutical Analysis (University of Strathclyde) and a BSc (Hons) in Analytical Chemistry (Glasgow Caledonian University).


Register now for this webinar